193 reports of this reaction
1.4% of all FOSAPREPITANT reports
#9 most reported adverse reaction
DUODENAL ULCER PERFORATION is the #9 most commonly reported adverse reaction for FOSAPREPITANT, manufactured by Actavis Pharma, Inc.. There are 193 FDA adverse event reports linking FOSAPREPITANT to DUODENAL ULCER PERFORATION. This represents approximately 1.4% of all 13,437 adverse event reports for this drug.
Patients taking FOSAPREPITANT who experience duodenal ulcer perforation should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
DUODENAL ULCER PERFORATION is a less commonly reported adverse event for FOSAPREPITANT, but still significant enough to appear in the safety profile.
In addition to duodenal ulcer perforation, the following adverse reactions have been reported for FOSAPREPITANT:
DUODENAL ULCER PERFORATION has been reported as an adverse event in 193 FDA reports for FOSAPREPITANT. This does not prove causation, but indicates an association observed in post-market surveillance data.
DUODENAL ULCER PERFORATION accounts for approximately 1.4% of all adverse event reports for FOSAPREPITANT, making it a notable side effect.
If you experience duodenal ulcer perforation while taking FOSAPREPITANT, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.